董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Phillip P. Chan | 男 | Chief Executive Officer and Director | 55 | 80.84万美元 | 210.01 | 2026-08-13 |
| Edward R. Jones | 男 | Independent Director | 77 | 8.04万美元 | 18.71 | 2026-08-13 |
| Alan D. Sobel | 男 | Independent Director | 65 | 10.68万美元 | 25.13 | 2026-08-13 |
| Michael G. Bator | 男 | Chairman of the Board and Director | 62 | 14.75万美元 | 31.86 | 2026-08-13 |
| Jiny Kim | 女 | Independent Director | 49 | 8.04万美元 | 10.59 | 2026-08-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Phillip P. Chan | 男 | Chief Executive Officer and Director | 55 | 80.84万美元 | 210.01 | 2026-08-13 |
| Vincent J. Capponi | 男 | Chief Operating Officer and President | 68 | 71.44万美元 | 117.90 | 2026-08-13 |
| Efthymios N. Deliargyris | 男 | Chief Medical Officer | 57 | 66.35万美元 | 61.83 | 2026-08-13 |
| Peter J. Mariani | 男 | Chief Financial Officer | 63 | 65.99万美元 | 17.06 | 2026-08-13 |
董事简历
中英对照 | 中文 | 英文- Phillip P. Chan
-
Phillip P. Chan是医学博士，获得博士学位。Dr. Chan于2008年担任该公司董事，还从2009年1月开始担任首席执行官。加入CytoSorbents前，Chan博士作为NJTC Investment Fund的合伙人领导了医疗保健与生命科学领域的投资。Chan博士与人合作创始安德鲁科技有限公司（Andrew Technologies），这是一家医疗设备公司，其将HydraSolveTM lipoplasty系统商业化，应用于整形手术。他是一位获认证的内科医生，其在临床医学与研究拥有强大的工作背景。Chan博士在耶鲁大学医学院（Yale University School of Medicine）获得医学博士与博士学位，并在贝斯以色列女执事医疗中心（Beth Israel Deaconess Medical Center）完成内科住院医师实习。他还在科内尔大学（Cornell University）获得细胞与分子生物学理学学士学位。
Phillip P. Chan has served as a director of CytoSorbents since July 2008, and has served as Cytosorbents Corporation's Chief Executive Officer since January 2009. Dr. Chan served as Cytosorbents Corporation's President from January 2009 to April 2020. Prior to joining CytoSorbents, Dr. Chan led healthcare and life science investments for the NJTC Venture Fund from 2003 to 2008, most recently as a Partner. Dr. Chan was a co founder and Vice Chairman of the Board of Directors of Medality Medical, Inc., fka Andrew Technologies, a medical device company that received U.S. Food and Drug Administration (FDA) 510(k) clearance of its HydraSolve lipoplasty system and completed a human clinical study using the system to remove visceral mesenteric fat as a potential surgical treatment of Type 2 diabetes. He is an Internal Medicine physician with a strong background in clinical medicine and research. Dr. Chan received his MD and PhD from the Yale University School of Medicine, completed his Internal Medicine residency at the Beth Israel Deaconess Medical Center at Harvard Medical School and received his Board certification. He also holds a BS in cell and molecular biology from Cornell University. - Phillip P. Chan是医学博士，获得博士学位。Dr. Chan于2008年担任该公司董事，还从2009年1月开始担任首席执行官。加入CytoSorbents前，Chan博士作为NJTC Investment Fund的合伙人领导了医疗保健与生命科学领域的投资。Chan博士与人合作创始安德鲁科技有限公司（Andrew Technologies），这是一家医疗设备公司，其将HydraSolveTM lipoplasty系统商业化，应用于整形手术。他是一位获认证的内科医生，其在临床医学与研究拥有强大的工作背景。Chan博士在耶鲁大学医学院（Yale University School of Medicine）获得医学博士与博士学位，并在贝斯以色列女执事医疗中心（Beth Israel Deaconess Medical Center）完成内科住院医师实习。他还在科内尔大学（Cornell University）获得细胞与分子生物学理学学士学位。
- Phillip P. Chan has served as a director of CytoSorbents since July 2008, and has served as Cytosorbents Corporation's Chief Executive Officer since January 2009. Dr. Chan served as Cytosorbents Corporation's President from January 2009 to April 2020. Prior to joining CytoSorbents, Dr. Chan led healthcare and life science investments for the NJTC Venture Fund from 2003 to 2008, most recently as a Partner. Dr. Chan was a co founder and Vice Chairman of the Board of Directors of Medality Medical, Inc., fka Andrew Technologies, a medical device company that received U.S. Food and Drug Administration (FDA) 510(k) clearance of its HydraSolve lipoplasty system and completed a human clinical study using the system to remove visceral mesenteric fat as a potential surgical treatment of Type 2 diabetes. He is an Internal Medicine physician with a strong background in clinical medicine and research. Dr. Chan received his MD and PhD from the Yale University School of Medicine, completed his Internal Medicine residency at the Beth Israel Deaconess Medical Center at Harvard Medical School and received his Board certification. He also holds a BS in cell and molecular biology from Cornell University.
- Edward R. Jones
-
Edward R. Jones是医学博士，获得工商管理硕士学位。Jones博士从2007年4月开始一直担任该公司的董事。Jones博士是爱因斯坦医疗中心（Albert Einstein Medical Center）和板栗山医院（Chestnut Hill Hospital）的主治内科医生，并担任天普大学医院（Temple University Hospital）的医学临床教授。Jones博士已向出版社发表或投稿关于与肾脏相关疾病的治疗方面主题的30章节、篇和摘要。他是肾脏病医师协会（Renal Physicians Association）、费城县医疗协会（Philadelphia County Medical Society）的有16年时间的会员，并是特拉华谷全国肾脏病基金会（National Kidney Foundation）的董事。Jones博士是肾脏病医师协会（Renal Physicians Association）的前总裁。
Edward R. Jones has served as a director of the Company since April 2007. Dr. Jones retired from the clinical practice of nephrology in January 2020. Dr. Jones has been an attending physician at Albert Einstein Medical Center and Chestnut Hill Hospital as well as Clinical Professor of Medicine at Temple University Hospital since 1985. Dr. Jones has published or contributed to the publishing of 30 chapters, articles, and abstracts on the subject of treating kidney related illnesses. He has been a member of the Renal Physicians Association, the Philadelphia County Medical Society for 17 years, and is a former board member of the National Kidney Foundation of the Delaware Valley. From March 2009 to March 2011, Dr. Jones served as President of, and Counselor at, the Renal Physicians Association. Dr. Jones is the former Chairman of Kidney Care Partners, and he served as former President of Delaware Valley Nephrology and Hypertension Associates. He retired from that practice on June 30, 2018. Dr. Jones graduated from the Medical University of South Carolina and completed his Internal Medicine residency at Temple University Hospital (TUH). He later served as Chief Medical Resident at Temple University Hospital. He was a fellow in the Renal and Electrolyte Section of the University of Pennsylvania after which he joined the faculty of Temple where he ran the renal physiology laboratory while teaching and providing patient care. Dr. Jones received his MBA in healthcare management from St. Joseph's University in Philadelphia. - Edward R. Jones是医学博士，获得工商管理硕士学位。Jones博士从2007年4月开始一直担任该公司的董事。Jones博士是爱因斯坦医疗中心（Albert Einstein Medical Center）和板栗山医院（Chestnut Hill Hospital）的主治内科医生，并担任天普大学医院（Temple University Hospital）的医学临床教授。Jones博士已向出版社发表或投稿关于与肾脏相关疾病的治疗方面主题的30章节、篇和摘要。他是肾脏病医师协会（Renal Physicians Association）、费城县医疗协会（Philadelphia County Medical Society）的有16年时间的会员，并是特拉华谷全国肾脏病基金会（National Kidney Foundation）的董事。Jones博士是肾脏病医师协会（Renal Physicians Association）的前总裁。
- Edward R. Jones has served as a director of the Company since April 2007. Dr. Jones retired from the clinical practice of nephrology in January 2020. Dr. Jones has been an attending physician at Albert Einstein Medical Center and Chestnut Hill Hospital as well as Clinical Professor of Medicine at Temple University Hospital since 1985. Dr. Jones has published or contributed to the publishing of 30 chapters, articles, and abstracts on the subject of treating kidney related illnesses. He has been a member of the Renal Physicians Association, the Philadelphia County Medical Society for 17 years, and is a former board member of the National Kidney Foundation of the Delaware Valley. From March 2009 to March 2011, Dr. Jones served as President of, and Counselor at, the Renal Physicians Association. Dr. Jones is the former Chairman of Kidney Care Partners, and he served as former President of Delaware Valley Nephrology and Hypertension Associates. He retired from that practice on June 30, 2018. Dr. Jones graduated from the Medical University of South Carolina and completed his Internal Medicine residency at Temple University Hospital (TUH). He later served as Chief Medical Resident at Temple University Hospital. He was a fellow in the Renal and Electrolyte Section of the University of Pennsylvania after which he joined the faculty of Temple where he ran the renal physiology laboratory while teaching and providing patient care. Dr. Jones received his MBA in healthcare management from St. Joseph's University in Philadelphia.
- Alan D. Sobel
-
Alan D. Sobel是注册会计师。Sobel先生从2014年11月开始一直担任该公司的董事。Sobel先生从1994年开始担任Sobel & Co., LLC的管理成员，这是一家全服务的会计、审计、税务和业务咨询公司。他为房地产、制造业、制药业和分销业务等行业内客户提供包括兼并与收购在内的公司顾问和咨询服务。Sobel先生是一位注册会计师，担任过多个领导职位，包括新泽西州注册会计师协会（New Jersey Society of Certified Public Accountants）的审计委员会主席。他在本特雷大学（Bentley College）获得会计学理学学士学位，并在菲尔莱狄更斯大学（Fairleigh Dickinson University）获得税务理学硕士学位。
Alan D. Sobel has served as a director of CytoSorbents since November 2014. Mr. Sobel is a Principal in the New Jersey Offices of CLA (CliftonLarsonAllen, LLP), serving in various positions since February 2023. Previously, since 1996, Mr. Sobel has served as the Managing Member of Sobel & Co., LLC, a full service accounting, auditing, taxation, and business consulting firm. He has provided corporate advisory and consulting services, including mergers and acquisitions, for clients in the real estate, manufacturing, pharmaceutical, and distribution businesses, among others. Mr. Sobel is a Certified Public Accountant and has served in various leadership roles including President of the New Jersey Society of Certified Public Accountants and Chairman of the Audit Committee of the New Jersey Society of Certified Public Accountants. Mr. Sobel received his BS in accounting from Bentley College and his MS in taxation from Fairleigh Dickenson University. - Alan D. Sobel是注册会计师。Sobel先生从2014年11月开始一直担任该公司的董事。Sobel先生从1994年开始担任Sobel & Co., LLC的管理成员，这是一家全服务的会计、审计、税务和业务咨询公司。他为房地产、制造业、制药业和分销业务等行业内客户提供包括兼并与收购在内的公司顾问和咨询服务。Sobel先生是一位注册会计师，担任过多个领导职位，包括新泽西州注册会计师协会（New Jersey Society of Certified Public Accountants）的审计委员会主席。他在本特雷大学（Bentley College）获得会计学理学学士学位，并在菲尔莱狄更斯大学（Fairleigh Dickinson University）获得税务理学硕士学位。
- Alan D. Sobel has served as a director of CytoSorbents since November 2014. Mr. Sobel is a Principal in the New Jersey Offices of CLA (CliftonLarsonAllen, LLP), serving in various positions since February 2023. Previously, since 1996, Mr. Sobel has served as the Managing Member of Sobel & Co., LLC, a full service accounting, auditing, taxation, and business consulting firm. He has provided corporate advisory and consulting services, including mergers and acquisitions, for clients in the real estate, manufacturing, pharmaceutical, and distribution businesses, among others. Mr. Sobel is a Certified Public Accountant and has served in various leadership roles including President of the New Jersey Society of Certified Public Accountants and Chairman of the Audit Committee of the New Jersey Society of Certified Public Accountants. Mr. Sobel received his BS in accounting from Bentley College and his MS in taxation from Fairleigh Dickenson University.
- Michael G. Bator
-
Michael G. Bator，他一直担任公司的董事（2015年7月以来）。2015年4月以来，他曾一直担任Trek Therapeutics公司（一个私人制药公司）的首席财务官。他也是Certus Advisory（他于2015年2月创立的咨询公司）的创始人兼合伙人。从2001年1月到2015年2月，他曾担任Jennison Associates（美国共同和养老基金管理公司）的一些职务，在那里他最近担任董事总经理、负责医疗研究。此前，他曾从事管理咨询，任职于Cambridge Pharma Consultancy、Lexington Strategy、The Boston Consulting Group。2015年3月以来，他曾任职于3DBio Corporation（一家私人公司，专注于用于重建和整形手术的打印的软骨移植）的董事会。他持有宾夕法尼亚大学的沃顿商学院（Wharton Business School at the University of Pennsylvania）的财务工商管理硕士学位，以及Princeton University的学士学位。
Michael G. Bator has served as a director of CytoSorbents since July 2015, and as Chairman of the Board since June 2023. Mr. Bator is a founder and partner of Quartz Advisory Group, LLC, a capital markets investment bank since November 2018. From April 2015 to December 2016, Mr. Bator was the Chief Financial Officer of Trek Therapeutics, a development stage pharmaceutical company. Mr. Bator has served as an advisor to IBF Venture Capital Fund, LLC since June 2015. From January 2001 until February 2015, Mr. Bator held several positions with Jennison Associates, a United States mutual and pension fund management company, where he was most recently Managing Director, Healthcare Research. Prior to that time, he worked in management consulting with Cambridge Pharma Consultancy, Lexington Strategy, and The Boston Consulting Group. Mr. Bator received his MBA in Finance from Wharton Business School at the University of Pennsylvania, and his BA from Princeton University. - Michael G. Bator，他一直担任公司的董事（2015年7月以来）。2015年4月以来，他曾一直担任Trek Therapeutics公司（一个私人制药公司）的首席财务官。他也是Certus Advisory（他于2015年2月创立的咨询公司）的创始人兼合伙人。从2001年1月到2015年2月，他曾担任Jennison Associates（美国共同和养老基金管理公司）的一些职务，在那里他最近担任董事总经理、负责医疗研究。此前，他曾从事管理咨询，任职于Cambridge Pharma Consultancy、Lexington Strategy、The Boston Consulting Group。2015年3月以来，他曾任职于3DBio Corporation（一家私人公司，专注于用于重建和整形手术的打印的软骨移植）的董事会。他持有宾夕法尼亚大学的沃顿商学院（Wharton Business School at the University of Pennsylvania）的财务工商管理硕士学位，以及Princeton University的学士学位。
- Michael G. Bator has served as a director of CytoSorbents since July 2015, and as Chairman of the Board since June 2023. Mr. Bator is a founder and partner of Quartz Advisory Group, LLC, a capital markets investment bank since November 2018. From April 2015 to December 2016, Mr. Bator was the Chief Financial Officer of Trek Therapeutics, a development stage pharmaceutical company. Mr. Bator has served as an advisor to IBF Venture Capital Fund, LLC since June 2015. From January 2001 until February 2015, Mr. Bator held several positions with Jennison Associates, a United States mutual and pension fund management company, where he was most recently Managing Director, Healthcare Research. Prior to that time, he worked in management consulting with Cambridge Pharma Consultancy, Lexington Strategy, and The Boston Consulting Group. Mr. Bator received his MBA in Finance from Wharton Business School at the University of Pennsylvania, and his BA from Princeton University.
- Jiny Kim
-
Jiny Kim自2022年4月起担任CytoSorbents的董事。Kim女士自2023年9月起担任Bausch HealthSolta Medical高级副总裁。此前，Kim女士在齐默巴奥米特控担任副总裁，担任Smart Implants产品组合的总经理，并在2021年6月至2023年8月期间负责领导齐默巴奥米特控的智能植入物技术在骨科领域的端到端项目和产品管理。在此之前，Kim女士于2020年2月至2021年5月在LivaNova担任全球战略营销副总裁兼神经调节和抑郁症总经理办公室主任。在此之前，Kim女士曾于2011年至2020年在Ethicon、强生医疗器械的美国销售和营销、业务发展（许可和收购）以及战略全球营销部门担任越来越多的职责。Kim女士在麻省理工学院斯隆管理学院获得MBA学位，她获得了宾夕法尼亚大学的双学位，获得了沃顿商学院的经济学学士学位和文理学院的政治学学士学位。
Jiny Kim has served as a director of CytoSorbents since April 2022. Ms. Kim has served as Senior Vice President at Solta Medical at Bausch Health since September 2023. Previously, Ms. Kim served as the Vice President at Zimmer Biomet, where she served as the general manager of the Smart Implants portfolio and was responsible for leading the end to end program and product management for Zimmer Biomet's Smart Implants technology in the orthopedic field from June 2021 to August 2023. Prior to this, Ms. Kim served as Vice President, Global Strategic Marketing and Chief of Staff for the General Manager, Neuromodulation and Depression at LivaNova from February 2020 to May 2021. Prior to this, Ms. Kim served in increasing roles of responsibility at Ethicon, Johnson & Johnson Medical Devices in U.S. Sales and Marketing, Business Development (Licensing and Acquisition), and Strategic Global Marketing from 2011 to 2020. Ms. Kim received her MBA at the MIT Sloan School of Management, and she received a dual degree from the University of Pennsylvania with a B.S. in Economics from The Wharton School and a B.A. in Political Science from The College of Arts and Sciences. - Jiny Kim自2022年4月起担任CytoSorbents的董事。Kim女士自2023年9月起担任Bausch HealthSolta Medical高级副总裁。此前，Kim女士在齐默巴奥米特控担任副总裁，担任Smart Implants产品组合的总经理，并在2021年6月至2023年8月期间负责领导齐默巴奥米特控的智能植入物技术在骨科领域的端到端项目和产品管理。在此之前，Kim女士于2020年2月至2021年5月在LivaNova担任全球战略营销副总裁兼神经调节和抑郁症总经理办公室主任。在此之前，Kim女士曾于2011年至2020年在Ethicon、强生医疗器械的美国销售和营销、业务发展（许可和收购）以及战略全球营销部门担任越来越多的职责。Kim女士在麻省理工学院斯隆管理学院获得MBA学位，她获得了宾夕法尼亚大学的双学位，获得了沃顿商学院的经济学学士学位和文理学院的政治学学士学位。
- Jiny Kim has served as a director of CytoSorbents since April 2022. Ms. Kim has served as Senior Vice President at Solta Medical at Bausch Health since September 2023. Previously, Ms. Kim served as the Vice President at Zimmer Biomet, where she served as the general manager of the Smart Implants portfolio and was responsible for leading the end to end program and product management for Zimmer Biomet's Smart Implants technology in the orthopedic field from June 2021 to August 2023. Prior to this, Ms. Kim served as Vice President, Global Strategic Marketing and Chief of Staff for the General Manager, Neuromodulation and Depression at LivaNova from February 2020 to May 2021. Prior to this, Ms. Kim served in increasing roles of responsibility at Ethicon, Johnson & Johnson Medical Devices in U.S. Sales and Marketing, Business Development (Licensing and Acquisition), and Strategic Global Marketing from 2011 to 2020. Ms. Kim received her MBA at the MIT Sloan School of Management, and she received a dual degree from the University of Pennsylvania with a B.S. in Economics from The Wharton School and a B.A. in Political Science from The College of Arts and Sciences.
高管简历
中英对照 | 中文 | 英文- Phillip P. Chan
Phillip P. Chan是医学博士，获得博士学位。Dr. Chan于2008年担任该公司董事，还从2009年1月开始担任首席执行官。加入CytoSorbents前，Chan博士作为NJTC Investment Fund的合伙人领导了医疗保健与生命科学领域的投资。Chan博士与人合作创始安德鲁科技有限公司（Andrew Technologies），这是一家医疗设备公司，其将HydraSolveTM lipoplasty系统商业化，应用于整形手术。他是一位获认证的内科医生，其在临床医学与研究拥有强大的工作背景。Chan博士在耶鲁大学医学院（Yale University School of Medicine）获得医学博士与博士学位，并在贝斯以色列女执事医疗中心（Beth Israel Deaconess Medical Center）完成内科住院医师实习。他还在科内尔大学（Cornell University）获得细胞与分子生物学理学学士学位。
Phillip P. Chan has served as a director of CytoSorbents since July 2008, and has served as Cytosorbents Corporation's Chief Executive Officer since January 2009. Dr. Chan served as Cytosorbents Corporation's President from January 2009 to April 2020. Prior to joining CytoSorbents, Dr. Chan led healthcare and life science investments for the NJTC Venture Fund from 2003 to 2008, most recently as a Partner. Dr. Chan was a co founder and Vice Chairman of the Board of Directors of Medality Medical, Inc., fka Andrew Technologies, a medical device company that received U.S. Food and Drug Administration (FDA) 510(k) clearance of its HydraSolve lipoplasty system and completed a human clinical study using the system to remove visceral mesenteric fat as a potential surgical treatment of Type 2 diabetes. He is an Internal Medicine physician with a strong background in clinical medicine and research. Dr. Chan received his MD and PhD from the Yale University School of Medicine, completed his Internal Medicine residency at the Beth Israel Deaconess Medical Center at Harvard Medical School and received his Board certification. He also holds a BS in cell and molecular biology from Cornell University.- Phillip P. Chan是医学博士，获得博士学位。Dr. Chan于2008年担任该公司董事，还从2009年1月开始担任首席执行官。加入CytoSorbents前，Chan博士作为NJTC Investment Fund的合伙人领导了医疗保健与生命科学领域的投资。Chan博士与人合作创始安德鲁科技有限公司（Andrew Technologies），这是一家医疗设备公司，其将HydraSolveTM lipoplasty系统商业化，应用于整形手术。他是一位获认证的内科医生，其在临床医学与研究拥有强大的工作背景。Chan博士在耶鲁大学医学院（Yale University School of Medicine）获得医学博士与博士学位，并在贝斯以色列女执事医疗中心（Beth Israel Deaconess Medical Center）完成内科住院医师实习。他还在科内尔大学（Cornell University）获得细胞与分子生物学理学学士学位。
- Phillip P. Chan has served as a director of CytoSorbents since July 2008, and has served as Cytosorbents Corporation's Chief Executive Officer since January 2009. Dr. Chan served as Cytosorbents Corporation's President from January 2009 to April 2020. Prior to joining CytoSorbents, Dr. Chan led healthcare and life science investments for the NJTC Venture Fund from 2003 to 2008, most recently as a Partner. Dr. Chan was a co founder and Vice Chairman of the Board of Directors of Medality Medical, Inc., fka Andrew Technologies, a medical device company that received U.S. Food and Drug Administration (FDA) 510(k) clearance of its HydraSolve lipoplasty system and completed a human clinical study using the system to remove visceral mesenteric fat as a potential surgical treatment of Type 2 diabetes. He is an Internal Medicine physician with a strong background in clinical medicine and research. Dr. Chan received his MD and PhD from the Yale University School of Medicine, completed his Internal Medicine residency at the Beth Israel Deaconess Medical Center at Harvard Medical School and received his Board certification. He also holds a BS in cell and molecular biology from Cornell University.
- Vincent J. Capponi
Vincent J. Capponi，Capponi先生于2002年加入该公司，担任运营部的副总裁，并于2005年7月担任其首席运营官。他在包括普强（Upjohn）、Sims Deltec和Sabratek在内的公司拥有超过20年的医疗设备、制药和成像设备的工作经验。于2002年加入CytoSorbents前，Capponi先生担任过Sabratek和其诊断部门GDS的几个高级管理职位，并于2001年担任GDS诊断部的临时总裁。从1998年到2000年，Capponi先生担任Sabratek的高级副总裁兼首席运营官，从1996年到1998年，担任运营部的副总裁。他在鲍灵格林大学（Bowling Green State University）获得化学理学硕士学位和化学与微生物学理学学士学位。
Vincent J. Capponi joined the Company as Vice President of Operations in 2002, became Cytosorbents Corporation's Chief Operating Officer in July 2005 and became President and Chief Operating Officer in April 2020 as well as Co Managing Director CytoSorbents MEA FZCO and Director and CytoSorbents India Private Limited. He has more than 30 years of management experience in medical device, pharmaceutical and imaging equipment at companies including Upjohn, Sims Deltec and Sabratek. Prior to joining CytoSorbents in 2002, Mr. Capponi held several senior management positions at Sabratek and its diagnostics division GDS and was interim president of GDS diagnostics in 2001. From 1998 to 2000, Mr. Capponi was Senior Vice President and Chief Operating Officer for Sabratek and Vice President Operations from 1996 to 1998. He received his MS in Chemistry and his BS in Chemistry and Microbiology from Bowling Green State University.- Vincent J. Capponi，Capponi先生于2002年加入该公司，担任运营部的副总裁，并于2005年7月担任其首席运营官。他在包括普强（Upjohn）、Sims Deltec和Sabratek在内的公司拥有超过20年的医疗设备、制药和成像设备的工作经验。于2002年加入CytoSorbents前，Capponi先生担任过Sabratek和其诊断部门GDS的几个高级管理职位，并于2001年担任GDS诊断部的临时总裁。从1998年到2000年，Capponi先生担任Sabratek的高级副总裁兼首席运营官，从1996年到1998年，担任运营部的副总裁。他在鲍灵格林大学（Bowling Green State University）获得化学理学硕士学位和化学与微生物学理学学士学位。
- Vincent J. Capponi joined the Company as Vice President of Operations in 2002, became Cytosorbents Corporation's Chief Operating Officer in July 2005 and became President and Chief Operating Officer in April 2020 as well as Co Managing Director CytoSorbents MEA FZCO and Director and CytoSorbents India Private Limited. He has more than 30 years of management experience in medical device, pharmaceutical and imaging equipment at companies including Upjohn, Sims Deltec and Sabratek. Prior to joining CytoSorbents in 2002, Mr. Capponi held several senior management positions at Sabratek and its diagnostics division GDS and was interim president of GDS diagnostics in 2001. From 1998 to 2000, Mr. Capponi was Senior Vice President and Chief Operating Officer for Sabratek and Vice President Operations from 1996 to 1998. He received his MS in Chemistry and his BS in Chemistry and Microbiology from Bowling Green State University.
- Efthymios N. Deliargyris
Efthymios N. Deliargyris于2020年5月1日加入公司，担任首席医疗官。Deliargyris博士是一名三级委员会认证医师（内科、心脏病学和介入心脏病学），在临床医学和学术界拥有杰出的职业生涯，并在担任全球领导职务方面拥有重要的生物技术经验。在加入CytoSorbents之前，Deliargyris博士于2018年8月至2020年4月期间担任PLx Pharma Inc.（纳斯达克股票代码：PLXP）的首席医疗官。在此之前，Deliargyris博士是Science and Strategy Consulting Group的创始人和董事总经理，为从事心血管领域的公司提供有关科学、监管、战略和商业化挑战的专家建议和解决方案。从2012年到2017年，Deliargyris博士在The Medicines Company担任心血管专营权的全球医疗主管，领导全球医疗战略、全球医疗事务和后期研发。在此之前，Deliargyris博士曾于2004年至2010年在希腊雅典雅典医疗中心担任心脏病学和介入心脏病学主任，并于2001年至2004年在北卡罗来纳州温斯顿塞勒姆的维克森林大学担任心脏病学助理教授和血管内实验室（IVUS）主任。Deliargyris博士在雅典Kapodistrian大学医学院获得医学博士学位，并在塔夫茨大学医学院完成了内科住院医师培训，并在北卡罗来纳大学教堂山分校完成了心脏病学和介入心脏病学研究金。
Efthymios N. Deliargyris joined the Company as Chief Medical Officer on May 1, 2020. Dr. Deliargyris is a triple board certified physician (internal medicine, cardiology and interventional cardiology) with a distinguished career in clinical medicine and academia and significant biotech experience in global leadership roles. Prior to joining CytoSorbents, Dr. Deliargyris served as the Chief Medical Officer of PLx Pharma Inc. (NASDAQ: PLXP) from August 2018 to April 2020. Prior to this, Dr. Deliargyris was the founder and managing director of the Science and Strategy Consulting Group providing expert advice and solutions on scientific, regulatory, strategic and commercialization challenges to companies engaging in the cardiovascular arena. From 2012 until 2017, Dr. Deliargyris served as Global Medical Lead of the Cardiovascular franchise at The Medicines Company where he led global medical strategy, global medical afairs and late stage R&D. Prior to this, Dr. Deliargyris served as Chief, Cardiology and Interventional Cardiology at Athens Medical Center in Athens, Greece from 2004 until 2010 and as Assistant Professor of Cardiology and Director of the Intravascular Laboratory (IVUS) at Wake Forest University in Winston Salem, NC from 2001 to 2004. Dr. Deliargyris received his Doctor of Medicine degree from the Kapodistrian University of Athens School of Medicine and completed his residency training in internal medicine at Tufts University School of Medicine and his fellowships in cardiology and interventional cardiology at the University of North Carolina at Chapel Hill.- Efthymios N. Deliargyris于2020年5月1日加入公司，担任首席医疗官。Deliargyris博士是一名三级委员会认证医师（内科、心脏病学和介入心脏病学），在临床医学和学术界拥有杰出的职业生涯，并在担任全球领导职务方面拥有重要的生物技术经验。在加入CytoSorbents之前，Deliargyris博士于2018年8月至2020年4月期间担任PLx Pharma Inc.（纳斯达克股票代码：PLXP）的首席医疗官。在此之前，Deliargyris博士是Science and Strategy Consulting Group的创始人和董事总经理，为从事心血管领域的公司提供有关科学、监管、战略和商业化挑战的专家建议和解决方案。从2012年到2017年，Deliargyris博士在The Medicines Company担任心血管专营权的全球医疗主管，领导全球医疗战略、全球医疗事务和后期研发。在此之前，Deliargyris博士曾于2004年至2010年在希腊雅典雅典医疗中心担任心脏病学和介入心脏病学主任，并于2001年至2004年在北卡罗来纳州温斯顿塞勒姆的维克森林大学担任心脏病学助理教授和血管内实验室（IVUS）主任。Deliargyris博士在雅典Kapodistrian大学医学院获得医学博士学位，并在塔夫茨大学医学院完成了内科住院医师培训，并在北卡罗来纳大学教堂山分校完成了心脏病学和介入心脏病学研究金。
- Efthymios N. Deliargyris joined the Company as Chief Medical Officer on May 1, 2020. Dr. Deliargyris is a triple board certified physician (internal medicine, cardiology and interventional cardiology) with a distinguished career in clinical medicine and academia and significant biotech experience in global leadership roles. Prior to joining CytoSorbents, Dr. Deliargyris served as the Chief Medical Officer of PLx Pharma Inc. (NASDAQ: PLXP) from August 2018 to April 2020. Prior to this, Dr. Deliargyris was the founder and managing director of the Science and Strategy Consulting Group providing expert advice and solutions on scientific, regulatory, strategic and commercialization challenges to companies engaging in the cardiovascular arena. From 2012 until 2017, Dr. Deliargyris served as Global Medical Lead of the Cardiovascular franchise at The Medicines Company where he led global medical strategy, global medical afairs and late stage R&D. Prior to this, Dr. Deliargyris served as Chief, Cardiology and Interventional Cardiology at Athens Medical Center in Athens, Greece from 2004 until 2010 and as Assistant Professor of Cardiology and Director of the Intravascular Laboratory (IVUS) at Wake Forest University in Winston Salem, NC from 2001 to 2004. Dr. Deliargyris received his Doctor of Medicine degree from the Kapodistrian University of Athens School of Medicine and completed his residency training in internal medicine at Tufts University School of Medicine and his fellowships in cardiology and interventional cardiology at the University of North Carolina at Chapel Hill.
- Peter J. Mariani
Peter J. Mariani在2011年6月加入Hansen，担任首席财务官。在2009年12月到2010年9月期间，Mariani先生曾是BMW Constructors, Inc.（一家私营的工业建设服务公司）的首席财务官和董事；在2007年1月到2009年1月期间，Mariani先生曾担任Harlan Laboratories（一家临床前期服务公司）的高级副总裁和首席财务官；在2006年4月到2006年11月期间，随着 Boston Scientific对Guidant Corporation的收购的完成，Mariani先生曾是Boston Scientific Corporation的法国集成协同项目办事处的副总裁；在1994年11月到2006年4月期间，Mariani先生曾在Guidant Corporation担任过各种高级财务阶层的职位，包括在2002年7月到2006年4月期间担任它的主管和首席会计师。Mariani先生是在Ernst & Young开始自己的职业生涯，在许多不同的行业（包括医疗卫生行业）中的私营和上市的公司客户担任审计经理。他拥有印第安纳大学（Indiana University）的会计学学士学位，并且还是一名注册会计师。
Peter J. Mariani has served as Cytosorbents Corporation's Chief Financial Officer since August 2024. Prior to joining CytoSorbents, Mr. Mariani served as Executive Vice President and Chief Financial Officer of Axogen, Inc (NASDAQ: AXGN), a medical technology company focused on peripheral nerve repair and regeneration from March 2021 to December 2023, and previously as its Chief Financial Officer from March 2016 to March 2021. At Axogen, Mr. Mariani was responsible for all finance and accounting functions, investor relations, information technology and security, and Global Quality. Prior to this, Mr. Mariani was the Chief Financial Officer of Lensar, Inc., from July 2014 to January 2016, which at the time was privately held and a global leader in next generation femtosecond laser technology for refractive cataract surgery. Prior to this, he served as Chief Financial Officer at Hansen Medical, Inc., from June 2011 to June 2014, a publicly traded company that designed and manufactured robotic solutions for intravascular procedures. Earlier in his career Mr. Mariani served in senior financial roles of increasing importance from November 1994 to December 2006 including Vice President and Corporate controller for Guidant Corporation, a $3.8 billion, publicly traded leader in the development and sale of medical devices for the treatment of cardiovascular disease. His experience at Guidant included Vice President of Finance and Administration, Guidant Japan from June 1998 to June 2002. He started his career at Ernst and Young, LLP, where he served a diverse client base as a Certified Public Accountant. Mr. Mariani earned a Bachelor of Science in accounting from Indiana University.- Peter J. Mariani在2011年6月加入Hansen，担任首席财务官。在2009年12月到2010年9月期间，Mariani先生曾是BMW Constructors, Inc.（一家私营的工业建设服务公司）的首席财务官和董事；在2007年1月到2009年1月期间，Mariani先生曾担任Harlan Laboratories（一家临床前期服务公司）的高级副总裁和首席财务官；在2006年4月到2006年11月期间，随着 Boston Scientific对Guidant Corporation的收购的完成，Mariani先生曾是Boston Scientific Corporation的法国集成协同项目办事处的副总裁；在1994年11月到2006年4月期间，Mariani先生曾在Guidant Corporation担任过各种高级财务阶层的职位，包括在2002年7月到2006年4月期间担任它的主管和首席会计师。Mariani先生是在Ernst & Young开始自己的职业生涯，在许多不同的行业（包括医疗卫生行业）中的私营和上市的公司客户担任审计经理。他拥有印第安纳大学（Indiana University）的会计学学士学位，并且还是一名注册会计师。
- Peter J. Mariani has served as Cytosorbents Corporation's Chief Financial Officer since August 2024. Prior to joining CytoSorbents, Mr. Mariani served as Executive Vice President and Chief Financial Officer of Axogen, Inc (NASDAQ: AXGN), a medical technology company focused on peripheral nerve repair and regeneration from March 2021 to December 2023, and previously as its Chief Financial Officer from March 2016 to March 2021. At Axogen, Mr. Mariani was responsible for all finance and accounting functions, investor relations, information technology and security, and Global Quality. Prior to this, Mr. Mariani was the Chief Financial Officer of Lensar, Inc., from July 2014 to January 2016, which at the time was privately held and a global leader in next generation femtosecond laser technology for refractive cataract surgery. Prior to this, he served as Chief Financial Officer at Hansen Medical, Inc., from June 2011 to June 2014, a publicly traded company that designed and manufactured robotic solutions for intravascular procedures. Earlier in his career Mr. Mariani served in senior financial roles of increasing importance from November 1994 to December 2006 including Vice President and Corporate controller for Guidant Corporation, a $3.8 billion, publicly traded leader in the development and sale of medical devices for the treatment of cardiovascular disease. His experience at Guidant included Vice President of Finance and Administration, Guidant Japan from June 1998 to June 2002. He started his career at Ernst and Young, LLP, where he served a diverse client base as a Certified Public Accountant. Mr. Mariani earned a Bachelor of Science in accounting from Indiana University.